On Tuesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) opened lower -0.93% from the last session, before settling in for the closing price of $2.14. Price fluctuations for IOVA have ranged from $1.64 to $12.51 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 4.17% over the past five years. Company’s average yearly earnings per share was noted 12.28% at the time writing. With a float of $292.67 million, this company’s outstanding shares have now reached $341.92 million.
Iovance Biotherapeutics Inc (IOVA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Iovance Biotherapeutics Inc is 19.12%, while institutional ownership is 53.78%. The most recent insider transaction that took place on Jun 05 ’25, was worth 55,200. In this transaction Chief Commercial Officer of this company bought 30,000 shares at a rate of $1.84, taking the stock ownership to the 30,000 shares. Before that another transaction happened on May 23 ’25, when Company’s Chief Regulatory Officer bought 5,600 for $1.74, making the entire transaction worth $9,743. This insider now owns 206,852 shares in total.
Iovance Biotherapeutics Inc (IOVA) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.28 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.3) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 50.61% during the next five years compared to 4.17% growth over the previous five years of trading.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Check out the current performance indicators for Iovance Biotherapeutics Inc (IOVA). In the past quarter, the stock posted a quick ratio of 2.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.63 in one year’s time.
